Skip to main content

. 1987 Mar;55(3):299–302. doi: 10.1038/bjc.1987.58

A cytotoxic DNA precursor is taken up selectively by human cancer xenografts.

K D Bagshawe, J Boden, G M Boxer, D W Britton, A Green, T Partridge, B Pedley, S Sharma, P Southall

PMCID: PMC2001750 PMID: 3567064

299

Images in this article

Figure 2
on p.301

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Akerblom L., Ehrenberg A., Gräslund A., Lankinen H., Reichard P., Thelander L. Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2159–2163. doi: 10.1073/pnas.78.4.2159. [DOI] [PMC free article] [PubMed] [Google Scholar]
Ariel I. M. Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors. Cancer. 1970 Mar;25(3):705–714. doi: 10.1002/1097-0142(197003)25:3<705::aid-cncr2820250331>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
Bagshawe K. D. Reversed-role chemotherapy for resistant cancer. Lancet. 1986 Oct 4;2(8510):778–781. doi: 10.1016/s0140-6736(86)90301-6. [DOI] [PubMed] [Google Scholar]
Benson A. B., 3rd, Trump D. L., Cummings K. B., Fischer P. H. Modulation of 5-iodo-2'-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines. Biochem Pharmacol. 1985 Nov 1;34(21):3925–3931. doi: 10.1016/0006-2952(85)90446-0. [DOI] [PubMed] [Google Scholar]
Curt G. A., Clendeninn N. J., Chabner B. A. Drug resistance in cancer. Cancer Treat Rep. 1984 Jan;68(1):87–99. [PubMed] [Google Scholar]
DJORDJEVIC B., SZYBALSKI W. Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med. 1960 Sep 1;112:509–531. doi: 10.1084/jem.112.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
Goldie J. H., Coldman A. J. Genetic instability in the development of drug resistance. Semin Oncol. 1985 Sep;12(3):222–230. [PubMed] [Google Scholar]
HAMPTON E. G., EIDINOFF M. L. Administration of 5-iododeoxyuridine-I-131 in the mouse and rat. Cancer Res. 1961 Apr;21:345–352. [PubMed] [Google Scholar]
Lewensohn R., Ringborg U., Hansson J. Different activities of unscheduled DNA synthesis in human melanoma and bone marrow cells. Cancer Res. 1982 Jan;42(1):84–88. [PubMed] [Google Scholar]
PRUSOFF W. H. A REVIEW OF SOME ASPECTS OF 5-IODODEOXYURIDINE AND AZAURIDINE. Cancer Res. 1963 Sep;23:1246–1259. [PubMed] [Google Scholar]
PRUSOFF W. H. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim Biophys Acta. 1959 Mar;32(1):295–296. doi: 10.1016/0006-3002(59)90597-9. [DOI] [PubMed] [Google Scholar]
Schuhmacher J., Kampmann H., Mattern J., Volm M., Wayss K., Zimmerer J. Incorporation of 131 iododeoxyuridine into the DNA of tumour-bearing rats after partial synchronization as a tool in scintigraphic tumour localization. Nucl Med (Stuttg) 1974 Jan 15;12(4):309–319. [PubMed] [Google Scholar]
Sneider T. W., Potter V. R. Alternative de novo and "salvage" pathways to thymidine triphosphate synthesis: possible implications for cancer chemotherapy. Cancer Res. 1969 Dec;29(12):2398–2403. [PubMed] [Google Scholar]
Tattersall M. H., Harrap K. R. Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil. Cancer Res. 1973 Dec;33(12):3086–3090. [PubMed] [Google Scholar]

ACTIONS

RESOURCES